All Stories

  1. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Matched-Case-Control Study
  2. Acoustic Emissions Dose and Spatial Control of Blood-Brain Barrier Opening with Focused Ultrasound
  3. Leptomeningeal metastatic disease: new frontiers and future directions
  4. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021
  5. Effect of adequacy of empirical antibiotic therapy for hospital-acquired bloodstream infections on intensive care unit patient prognosis: a causal inference approach using data from the Eurobact2 study
  6. Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions
  7. BIOS-01. MACHINE LEARNING-BASED PREDICTION OF INPATIENT CARE COSTS FOR PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS
  8. BIOS-04. THERAPIES FOR LEPTOMENINGEAL DISEASE: A NETWORK META-ANALYSIS
  9. CTNI-32. A MULTICENTER PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER2 POSITIVE BREAST CANCER (TUTOR)
  10. EPID-14. PATTERNS OF CARE AND PROGNOSTIC FACTORS FOR PATIENTS WITH BRAIN METASTASES FROM COLON CANCER: A REAL-WORLD STUDY
  11. EPID-15. INPATIENT CARE COSTS AND ASSOCIATED REIMBURSEMENTS FOR PATIENTS WITH LEPTOMENINGEAL DISEASE: A REAL-WORLD ANALYSIS
  12. EPID-17. REAL-WORLD OUTCOMES OF BRAIN METASTASES FROM PANCREATIC CANCER: AN ANALYSIS OF 1266 PATIENTS
  13. EPID-18. PATTERNS OF CARE AND CLINICAL OUTCOMES OF PATIENTS WITH GLIOBLASTOMA FROM 2005-2020: A REAL-WORLD ANALYSIS
  14. INNV-15. A PIVOTAL, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR PLASMA-BASED LIQUID BIOPSY IN PATIENTS WITH GLIOBLASTOMA (LIBERATE)
  15. RTID-03. A MULTICENTER, RANDOMIZED, CONTROLLED TRIAL OF FOCUSED-ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER DISRUPTION PLUS SYSTEMIC PEMBROLIZUMAB FOR PATIENTS WITH NSCLC BRAIN METASTASES (LIMITLESS)
  16. RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
  17. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  18. Program Signaling and Geographic Preferences in the United States Residency Match for Neurosurgery
  19. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  20. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  21. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  22. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  23. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  24. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  25. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  26. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  27. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  28. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  29. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  30. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  31. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  32. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  33. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  34. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  35. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  36. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  37. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  38. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  39. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  40. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  41. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  42. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  43. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  44. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  45. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  46. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  47. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  48. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  49. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  50. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  51. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  52. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  53. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  54. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  55. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  56. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  57. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  58. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  59. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  60. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  61. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  62. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  63. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  64. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  65. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  66. A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
  67. Presentation, management, and outcomes of older compared to younger adults with hospital-acquired bloodstream infections in the intensive care unit: a multicenter cohort study
  68. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  69. A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).
  70. Examining global and gender disparities in high-impact evidence synthesis on lung cancer: A 2000-2024 analysis of Cochrane Library.
  71. Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers.
  72. Pulmonary contusion with hemoptysis from lacrosse ball strike: A case report
  73. Burden of disease scenarios for 204 countries
  74. MP08-17 OUTCOMES OF INVASIVE PRIMARY URETHRAL CANCER IN WOMEN (IPUC): AN ANALYSIS FROM THE NATIONAL CANCER DATABASE
  75. Correction: The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  76. 151 Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis From a Multicenter Trial
  77. 501 Systemic Immunological Suppression in Glioblastoma Is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) From a Randomized Controlled Trial
  78. Safety and Feasibility of JAK Inhibitor Ruxolitinib in Newly-Diagnosed High-Grade Gliomas (CRUX): Final Trial Report
  79. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma
  80. The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  81. Disparities in Noninvasive Traditional and Advanced Testing for Coronary Artery Disease: Findings from the INCAPS-COVID 2 Study
  82. Outcomes of invasive primary urethral cancer in women: An analysis from the national cancer database
  83. Treatment strategies and survival outcomes in Non-invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database
  84. “Open-window” craniectomy for the removal of frontal sinus mucosa to prevent a delayed mucocele: illustrative case
  85. Symptomatic Cerebellar Ptosis following Cerebellar Hematoma Evacuation: A Case Report and Review of the Literature
  86. Treatment Strategies for Primary Cavernous Sinus Meningiomas: A Systematic Review and Meta-analysis
  87. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial
  88. Financial barriers and inequity in medical education in India: challenges to training a diverse and representative healthcare workforce
  89. Impact of tissue-agnostic approvals on management of primary brain tumors
  90. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
  91. Management of Brain Metastases: A Review of Novel Therapies
  92. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm
  93. Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries
  94. CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  95. CTNI-21. PHASE I STUDY OF BTK INHIBITOR IBRUTINIB WITH TEMOZOLOMIDE AND RADIATION IN NEWLY-DIAGNOSED GLIOBLASTOMA (EQUILIBRIUM): FINAL TRIAL REPORT
  96. CTNI-55. A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  97. DNAR-05. EXCEPTIONAL RESPONDERS TO BASE EXCISION REPAIR (BER) INHIBITION FOR RECURRENT GLIOBLASTOMA DISPLAY ENRICHMENT FOR DNA DAMAGE RESPONSE PATHWAYS: RNA SEQUENCING ANALYSIS FROM A MULTICENTER TRIAL
  98. IMMU-02. IS DUAL AGENT IMMUNOTHERAPY SHIFTING THE EPIDEMIOLOGY OF MELANOMA BRAIN METASTASES? A REAL-WORLD ANALYSIS AND SINGLE-INSTITUTION VALIDATION
  99. IMMU-34. SYSTEMIC IMMUNE SUPPRESSION IN GLIOBLASTOMA IS TARGETED BY CONCURRENT VEGF AND PD-1 INHIBITION IN A DOSE-DEPENDENT MANNER: TRANSCRIPTOMIC FINDINGS THROUGH CITE-SEQ FROM A RANDOMIZED CONTROLLED TRIAL
  100. RTID-01. A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  101. SURG-27. 17-YEAR EXPERIENCE OF SURGICAL MANAGEMENT OF INTRADURAL EXTRAMEDULLARY (IDEM) TUMORS: CLINICAL OUTCOMES FROM A LOW- AND MIDDLE-INCOME COUNTRY
  102. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients
  103. Management of Postoperative Discitis with Debridement and Novel Technique of Local Antibiotic Instillation: Functional Outcomes from a Resource-Limited Setting
  104. Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
  105. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
  106. P03.15.B SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT GLIOBLASTOMA: INITIAL OUTCOMES FROM A PROSPECTIVE MULTICENTER REGISTRY
  107. P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
  108. P07.13.B A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  109. P14.11.B A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  110. JS06.5.A TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  111. Neurosurgeon’s Ode to Meningiomas
  112. Authors' Response to Letter Regarding ‘The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators’ (Preprint)
  113. Authors' Reply to: Research Training For Medical Students To Stand Out In Residency Applications. Comment on "The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and ...
  114. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
  115. Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
  116. Enhancing lung cancer screening through ‘Saved by the Scan’: Lessons from a multipronged public service advertising program.
  117. Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
  118. Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.
  119. Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
  120. Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis.
  121. Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder.
  122. Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
  123. Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.
  124. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
  125. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  126. Authorship Diversity in Urology: 1998-2022 Cochrane Review Analysis
  127. Diploic Bone Channel Drilling Facilitates Dissection of the Midline Dura and Protects the Superior Sagittal Sinus in Hyperostosis Frontalis Interna
  128. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM)
  129. DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
  130. Who coauthors Cochrane Reviews related to genitourinary cancers? A 1998-2022 analysis of country and gender diversity.
  131. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
  132. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study
  133. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  134. Monitoring committees in clinical trials
  135. Phases of clinical trials
  136. Correlation
  137. List of contributors
  138. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study
  139. Novel Therapeutic Approaches in Neoplastic Meningitis
  140. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis
  141. Inequities in Country- and Gender-Based Authorship Representation in Cardiology-Related Cochrane Reviews
  142. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study (Preprint)
  143. The Future of Pulmonary Medicine Physician Work-Force in India
  144. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
  145. Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
  146. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis
  147. COVID-19-Associated Mucormycosis in a Tertiary Care Hospital in India: A Case Series
  148. Intracranial Pressure Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
  149. Authorship Diversity in Cochrane Systematic Reviews of Stroke: Inequities in Global Representation (P18-2.002)
  150. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
  151. Rising Inequity and Disparities in Medical Education in India: Challenges to Training a Representative Workforce (Preprint)
  152. Advanced subspecialty cardiology training in India in 2022: challenges and future directions
  153. Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study
  154. COUNTRY AND GENDER DIVERSITY IN CARDIOLOGY-RELATED COCHRANE REVIEWS: INEQUITIES IN GLOBAL REPRESENTATION
  155. Total hip arthroplasty for failed osteosynthesis of proximal femoral fractures: Clinical outcomes from a low- and middle-income country
  156. Overseas Medical Students in Ukraine and War-Related Interruption in Education: Global Health Considerations from India
  157. Management of postoperative discitis with debridement and local antibiotic infusion: functional outcomes from a low-middle-income country
  158. Functional outcomes after modified Blair's procedure for ankle arthritis secondary to Hawkins type III talus injuries: A retrospective cohort study
  159. In Reply: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  160. The perceived impact of the Covid-19 pandemic on medical student education and training – an international survey
  161. Educating the Next Generation of Global Neurosurgeons: Competencies, Skills, and Resources for Medical Students Interested in Global Neurosurgery
  162. Percutaneous image-guided cryoablation of spinal metastases: A systematic review
  163. Pediatric Brain Tumors: From Modern Classification System to Current Principles of Management
  164. BJS commission on surgery and perioperative care post-COVID-19
  165. Comparison of Blister Aneurysm Treatment Techniques: A Systematic Review and Meta-Analysis
  166. Impact of COVID-19 on Diagnostic Cardiac Procedural Volume in Oceania: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  167. Learning to practice medicine during COVID-19 and mucormycosis epidemics: an intern perspective from India
  168. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  169. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World
  170. Lessons from the life of Asia’s first female neurosurgeon for modern neurosurgical trainees and educators worldwide
  171. MP67-14 SCIENTIFIC AUTHORSHIP OF COCHRANE SYSTEMATIC REVIEWS IN UROLOGY: A 2020 ANALYSIS
  172. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia
  173. State of Accredited Endovascular Neurosurgery Training in India in 2021: Challenges to Capacity Building in Subspecialty Neurosurgical Care
  174. The Perceived Impact of the Covid-19 Pandemic on Medical Student Education and Training – An International Survey
  175. SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
  176. Letter: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  177. Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
  178. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe
  179. Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
  180. Anxiety, Uncertainty, and Resilience of Medical Students Worldwide during the COVID-19 Pandemic
  181. Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
  182. Abstract 831: State of medical and surgical oncology training in India: An infrastructural challenge to delivering high-quality cancer care
  183. Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study
  184. Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol
  185. Letter to the Editor Regarding “Characterizing the Effect of Pass/Fail U.S. Medical Licensing Examination Step 1 Scoring in Neurosurgery: Program Directors' Perspectives”
  186. The perceived global impact of the COVID‐19 pandemic on doctors’ medical and surgical training: An international survey
  187. Antibiotics for treatment of irritable bowel syndrome in adults
  188. Medical Students in Global Neurosurgery: Rationale and Role
  189. Retractions and Withdrawals in Neurology Literature: A 2020 Analysis of the Retraction Watch Database (2668)
  190. The perceived global impact of the COVID-19 pandemic on doctors’ medical and surgical training: an international survey
  191. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
  192. Timing of surgery following SARS-CoV-2 infection
  193. Biographies of international women leaders in neurosurgery
  194. Decline of Empathy During Medical Education
  195. Decline of Empathy During Medical Education
  196. Delivering High-Quality, Equitable Care in India: An Ethically-Resilient Framework for Healthcare Innovation After COVID-19
  197. Letter by Ozair et al Regarding Article, “The Upcoming Epidemic of Heart Failure in South Asia”
  198. International Impact of COVID-19 on the Diagnosis of Heart Disease
  199. SARS-CoV-2 Vaccination in India: Considerations of Hesitancy and Bioethics in Global Health
  200. Large Cerebral Infarction in Tuberculous Meningitis: Case Report of an Uncommon Complication
  201. Scrub Typhus Presenting with Hemiparesis: Case Report of a Rare Manifestation
  202. 0.54111/0001/vv16
  203. Adherence to Lockdown and Social-Distancing Policies Amidst COVID-19 Pandemic: A Behavioral and Socio-Economic Perspective from India
  204. Letter to the Editor Regarding “Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match”
  205. ACUTE FATTY LIVER OF PREGNANCY PRESENTING AS INTRAUTERINE FETAL DEATH, POSTPARTUM HEMORRHAGE AND MULTI-ORGAN FAILURE: NEED FOR A MULTI-DISCIPLINARY, INTENSIVIST-LED MANAGEMENT
  206. Learning high‐value care in developing countries
  207. Why are India’s Best Medical Graduates not Preferring ENT for Postgraduate Training Through NEET-PG?
  208. Abstracts from the International Science Symposium on HIV and Infectious Diseases (ISSHID 2019): Infectious diseases
  209. Scrub Typhus: Case of a Rare Etiology Behind Intracerebral Hemorrhage (204)
  210. Stroke in persons with disability
  211. Postoperative urinary retention: A controlled trial of fixed-dose spinal anesthesia using bupivacaine versus ropivacaine
  212. Transhepatic intraperitoneally migrated biliary stent: A rare finding during laparoscopic cholecystectomy
  213. Training and Delivery of Critical Care Medicine in India: Concerns Revealed by COVID-19 Pandemic
  214. A rare etiology behind isolated lateral rectus palsy: Scrub typhus
  215. Scrub typhus manifesting with intracerebral hemorrhage: Case report and review of literature
  216. Impaled roadside guardrail in the neck: Case of a failed motorcycle stunt
  217. Academic quality of incoming ophthalmology residents in India: Concerns for the future
  218. Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the dual challenge of psychosocial issues and an uncommon medical condition
  219. Upsurge of chikungunya cases in Uttar Pradesh, India
  220. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  221. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators